Notice of Annual General Meeting and Annual Report

RNS Number : 5003E

e-Therapeutics plc

08 May 2017

 

e-Therapeutics plc

('e-Therapeutics' or the 'Company')

Notice of Annual General Meeting and Annual Report

Oxford, UK, 8 May 2017 - e-Therapeutics plc (AIM: ETX) announces that its annual report and accounts for the year ended 31 January 2017, which includes the notice convening the Company's 2017 Annual General Meeting (AGM), has been posted to shareholders today.

An electronic copy of the annual report can be downloaded from the Company's website at www.etherapeutics.co.uk/investors/financial-reports  

The 2017 AGM will take place at 11:00 am on 31 May 2017 at the offices of Stephenson Harwood LLP, 1 Finsbury Circus, London EC2M 7SH.

-Ends-

Contacts:

e-Therapeutics plc Ray Barlow, CEO Steve Medlicott, Finance Director	Tel: [phone] www.etherapeutics.co.uk
Numis Securities Limited Michael Meade / Freddie Barnfield (Nominated Adviser) James Black (Corporate Broking)	Tel: [phone] www.numis.com
Instinctif Partners Melanie Toyne Sewell / Alex Shaw	Tel: [phone] Email: [e-mail]

About e-Therapeutics plc

e-Therapeutics is a drug discovery company with a unique and proprietary in silico discovery platform.  The Company is applying its computational platform to the discovery of new drug candidates for which it can secure robust intellectual property rights.

The therapeutic focus of the Company's discovery activity is in areas of complex disease with unmet medical need, including immuno-oncology.  The business model is to partner these preclinical drug candidates.

e-Therapeutics is headquartered in Oxford. For more information about the Company please visit www.etherapeutics.co.uk.

 

END

 

 

NOAUGUGUAUPMGCR